CA2371604A1 - Integrin receptor antagonists - Google Patents

Integrin receptor antagonists Download PDF

Info

Publication number: CA2371604A1
Authority: CA; Canada
Prior art keywords: gly; bala; bhs; phhs; tolhs
Prior art date: 1999-04-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002371604A

Other languages

English (en)

French (fr)

Inventor

Andreas Kling

Udo Lange

Arnulf Lauterbach

Herve Geneste

Thomas Subkowski

Johann-Christian Zechel

Claudia Isabella Graef

Wilfried Hornberger

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott GmbH and Co KG

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-28

Filing date

2000-04-17

Publication date

2000-11-09

1999-04-28 Priority claimed from DE1999119218 external-priority patent/DE19919218A1/de

1999-10-06 Priority claimed from DE1999148269 external-priority patent/DE19948269A1/de

2000-04-17 Application filed by Individual filed Critical Individual

2000-11-09 Publication of CA2371604A1 publication Critical patent/CA2371604A1/en

Status Abandoned legal-status Critical Current

Links

229940127449 Integrin Receptor Antagonists Drugs 0.000 title abstract description 7
150000001875 compounds Chemical class 0.000 claims abstract description 64
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 24
102000006495 integrins Human genes 0.000 claims abstract description 19
108010044426 integrins Proteins 0.000 claims abstract description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
201000010099 disease Diseases 0.000 claims abstract 4
-1 C1-C6-alkyl radical Chemical class 0.000 claims description 237
150000003254 radicals Chemical class 0.000 claims description 105
125000003118 aryl group Chemical group 0.000 claims description 62
229920006395 saturated elastomer Polymers 0.000 claims description 50
229910052757 nitrogen Inorganic materials 0.000 claims description 41
125000005842 heteroatom Chemical group 0.000 claims description 39
125000000623 heterocyclic group Chemical group 0.000 claims description 38
229910052717 sulfur Inorganic materials 0.000 claims description 38
229910052739 hydrogen Inorganic materials 0.000 claims description 34
239000001257 hydrogen Substances 0.000 claims description 34
229910052760 oxygen Inorganic materials 0.000 claims description 34
239000005557 antagonist Substances 0.000 claims description 22
150000002431 hydrogen Chemical group 0.000 claims description 19
125000002877 alkyl aryl group Chemical group 0.000 claims description 15
210000004027 cell Anatomy 0.000 claims description 13
125000003107 substituted aryl group Chemical group 0.000 claims description 13
229910052736 halogen Inorganic materials 0.000 claims description 12
150000002367 halogens Chemical class 0.000 claims description 12
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 11
125000001424 substituent group Chemical group 0.000 claims description 9
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 8
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
210000001772 blood platelet Anatomy 0.000 claims description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
238000006467 substitution reaction Methods 0.000 claims description 7
206010028980 Neoplasm Diseases 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
208000027418 Wounds and injury Diseases 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 4
230000015572 biosynthetic process Effects 0.000 claims description 4
230000006378 damage Effects 0.000 claims description 4
230000000694 effects Effects 0.000 claims description 4
208000014674 injury Diseases 0.000 claims description 4
102000005962 receptors Human genes 0.000 claims description 4
108020003175 receptors Proteins 0.000 claims description 4
201000001320 Atherosclerosis Diseases 0.000 claims description 3
125000006519 CCH3 Chemical group 0.000 claims description 3
206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
206010019280 Heart failures Diseases 0.000 claims description 3
206010061218 Inflammation Diseases 0.000 claims description 3
208000001132 Osteoporosis Diseases 0.000 claims description 3
108090000190 Thrombin Proteins 0.000 claims description 3
230000033115 angiogenesis Effects 0.000 claims description 3
230000004054 inflammatory process Effects 0.000 claims description 3
239000000651 prodrug Substances 0.000 claims description 3
229940002612 prodrug Drugs 0.000 claims description 3
208000037803 restenosis Diseases 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
229960004072 thrombin Drugs 0.000 claims description 3
230000029663 wound healing Effects 0.000 claims description 3
208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
206010003178 Arterial thrombosis Diseases 0.000 claims description 2
208000037147 Hypercalcaemia Diseases 0.000 claims description 2
201000002980 Hyperparathyroidism Diseases 0.000 claims description 2
206010020772 Hypertension Diseases 0.000 claims description 2
208000010191 Osteitis Deformans Diseases 0.000 claims description 2
208000003076 Osteolysis Diseases 0.000 claims description 2
208000027868 Paget disease Diseases 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims description 2
208000033626 Renal failure acute Diseases 0.000 claims description 2
201000011040 acute kidney failure Diseases 0.000 claims description 2
238000002399 angioplasty Methods 0.000 claims description 2
230000000148 hypercalcaemia Effects 0.000 claims description 2
208000030915 hypercalcemia disease Diseases 0.000 claims description 2
208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 2
230000003211 malignant effect Effects 0.000 claims description 2
208000027202 mammary Paget disease Diseases 0.000 claims description 2
230000001394 metastastic effect Effects 0.000 claims description 2
206010061289 metastatic neoplasm Diseases 0.000 claims description 2
206010062198 microangiopathy Diseases 0.000 claims description 2
230000003071 parasitic effect Effects 0.000 claims description 2
230000035755 proliferation Effects 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
230000003612 virological effect Effects 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims 14
229940079593 drug Drugs 0.000 claims 12
239000003814 drug Substances 0.000 claims 12
239000000546 pharmaceutical excipient Substances 0.000 claims 11
229940124531 pharmaceutical excipient Drugs 0.000 claims 11
239000002412 selectin antagonist Substances 0.000 claims 5
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
230000001404 mediated effect Effects 0.000 claims 4
239000005541 ACE inhibitor Substances 0.000 claims 3
125000003601 C2-C6 alkynyl group Chemical class 0.000 claims 3
229940127291 Calcium channel antagonist Drugs 0.000 claims 3
229920002683 Glycosaminoglycan Polymers 0.000 claims 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 3
102000002274 Matrix Metalloproteinases Human genes 0.000 claims 3
108010000684 Matrix Metalloproteinases Proteins 0.000 claims 3
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 3
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 3
230000002776 aggregation Effects 0.000 claims 3
238000004220 aggregation Methods 0.000 claims 3
229940127282 angiotensin receptor antagonist Drugs 0.000 claims 3
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 3
239000003963 antioxidant agent Substances 0.000 claims 3
239000000480 calcium channel blocker Substances 0.000 claims 3
229960002897 heparin Drugs 0.000 claims 3
229920000669 heparin Polymers 0.000 claims 3
229940127215 low-molecular weight heparin Drugs 0.000 claims 3
229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 3
239000005483 tyrosine kinase inhibitor Substances 0.000 claims 3
102000055006 Calcitonin Human genes 0.000 claims 2
108060001064 Calcitonin Proteins 0.000 claims 2
102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 2
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 2
102000004890 Interleukin-8 Human genes 0.000 claims 2
108090001007 Interleukin-8 Proteins 0.000 claims 2
208000006011 Stroke Diseases 0.000 claims 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
206010053648 Vascular occlusion Diseases 0.000 claims 2
230000004913 activation Effects 0.000 claims 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 2
229960004015 calcitonin Drugs 0.000 claims 2
201000011510 cancer Diseases 0.000 claims 2
230000036755 cellular response Effects 0.000 claims 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
201000009101 diabetic angiopathy Diseases 0.000 claims 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
208000010125 myocardial infarction Diseases 0.000 claims 2
239000002464 receptor antagonist Substances 0.000 claims 2
229940044551 receptor antagonist Drugs 0.000 claims 2
208000021331 vascular occlusion disease Diseases 0.000 claims 2
102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
208000035143 Bacterial infection Diseases 0.000 claims 1
229940122361 Bisphosphonate Drugs 0.000 claims 1
229940123861 Bone formation stimulant Drugs 0.000 claims 1
102100032912 CD44 antigen Human genes 0.000 claims 1
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 claims 1
102000011727 Caspases Human genes 0.000 claims 1
108010076667 Caspases Proteins 0.000 claims 1
102000029816 Collagenase Human genes 0.000 claims 1
108060005980 Collagenase Proteins 0.000 claims 1
229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
108010074860 Factor Xa Proteins 0.000 claims 1
229940123457 Free radical scavenger Drugs 0.000 claims 1
229940121672 Glycosylation inhibitor Drugs 0.000 claims 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
102000002265 Human Growth Hormone Human genes 0.000 claims 1
108010000521 Human Growth Hormone Proteins 0.000 claims 1
239000000854 Human Growth Hormone Substances 0.000 claims 1
102100022339 Integrin alpha-L Human genes 0.000 claims 1
108010008212 Integrin alpha4beta1 Proteins 0.000 claims 1
102000000589 Interleukin-1 Human genes 0.000 claims 1
108010002352 Interleukin-1 Proteins 0.000 claims 1
102000000743 Interleukin-5 Human genes 0.000 claims 1
108010002616 Interleukin-5 Proteins 0.000 claims 1
229940127448 Interleukin-6 Antagonists Drugs 0.000 claims 1
229940122472 LDL receptor function stimulant Drugs 0.000 claims 1
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
229940123313 MCP-1 antagonist Drugs 0.000 claims 1
208000030852 Parasitic disease Diseases 0.000 claims 1
229940123924 Protein kinase C inhibitor Drugs 0.000 claims 1
229940122388 Thrombin inhibitor Drugs 0.000 claims 1
208000007536 Thrombosis Diseases 0.000 claims 1
230000000118 anti-neoplastic effect Effects 0.000 claims 1
239000003146 anticoagulant agent Substances 0.000 claims 1
229940127219 anticoagulant drug Drugs 0.000 claims 1
238000011444 antiresorptive therapy Methods 0.000 claims 1
239000002876 beta blocker Substances 0.000 claims 1
229940097320 beta blocking agent Drugs 0.000 claims 1
150000004663 bisphosphonates Chemical class 0.000 claims 1
210000004369 blood Anatomy 0.000 claims 1
239000008280 blood Substances 0.000 claims 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
235000012000 cholesterol Nutrition 0.000 claims 1
230000015271 coagulation Effects 0.000 claims 1
238000005345 coagulation Methods 0.000 claims 1
229960002424 collagenase Drugs 0.000 claims 1
230000000295 complement effect Effects 0.000 claims 1
239000004074 complement inhibitor Substances 0.000 claims 1
239000000824 cytostatic agent Substances 0.000 claims 1
230000001085 cytostatic effect Effects 0.000 claims 1
239000003166 dihydrofolate reductase inhibitor Substances 0.000 claims 1
239000002308 endothelin receptor antagonist Substances 0.000 claims 1
238000002657 hormone replacement therapy Methods 0.000 claims 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
229960003444 immunosuppressant agent Drugs 0.000 claims 1
239000003018 immunosuppressive agent Substances 0.000 claims 1
238000002513 implantation Methods 0.000 claims 1
229940096397 interleukin-8 Drugs 0.000 claims 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 1
230000023404 leukocyte cell-cell adhesion Effects 0.000 claims 1
239000003055 low molecular weight heparin Substances 0.000 claims 1
239000000236 nitric oxide synthase inhibitor Substances 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
230000037361 pathway Effects 0.000 claims 1
239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
230000010118 platelet activation Effects 0.000 claims 1
230000002062 proliferating effect Effects 0.000 claims 1
239000003881 protein kinase C inhibitor Substances 0.000 claims 1
239000002516 radical scavenger Substances 0.000 claims 1
CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 claims 1
239000003001 serine protease inhibitor Substances 0.000 claims 1
230000019491 signal transduction Effects 0.000 claims 1
102000009076 src-Family Kinases Human genes 0.000 claims 1
108010087686 src-Family Kinases Proteins 0.000 claims 1
239000000021 stimulant Substances 0.000 claims 1
239000003868 thrombin inhibitor Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 18
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
125000004093 cyano group Chemical group *C#N 0.000 description 11
150000005840 aryl radicals Chemical class 0.000 description 10
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 8
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
125000001072 heteroaryl group Chemical group 0.000 description 6
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
150000001412 amines Chemical group 0.000 description 5
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 4
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 4
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 4
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 4
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 4
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
229910052794 bromium Inorganic materials 0.000 description 4
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
229910052740 iodine Inorganic materials 0.000 description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 3
125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 3
125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 3
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 3
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 3
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 3
125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 3
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 3
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 3
125000006050 3-methyl-2-pentenyl group Chemical group 0.000 description 3
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
239000003446 ligand Substances 0.000 description 3
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 3
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
230000004962 physiological condition Effects 0.000 description 3
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 3
125000006079 1,1,2-trimethyl-2-propenyl group Chemical group 0.000 description 2
125000006059 1,1-dimethyl-2-butenyl group Chemical group 0.000 description 2
125000006033 1,1-dimethyl-2-propenyl group Chemical group 0.000 description 2
125000006060 1,1-dimethyl-3-butenyl group Chemical group 0.000 description 2
125000006062 1,2-dimethyl-2-butenyl group Chemical group 0.000 description 2
125000006035 1,2-dimethyl-2-propenyl group Chemical group 0.000 description 2
125000006063 1,2-dimethyl-3-butenyl group Chemical group 0.000 description 2
125000006065 1,3-dimethyl-2-butenyl group Chemical group 0.000 description 2
125000006066 1,3-dimethyl-3-butenyl group Chemical group 0.000 description 2
125000006080 1-ethyl-1-methyl-2-propenyl group Chemical group 0.000 description 2
125000006074 1-ethyl-2-butenyl group Chemical group 0.000 description 2
125000006082 1-ethyl-2-methyl-2-propenyl group Chemical group 0.000 description 2
125000006037 1-ethyl-2-propenyl group Chemical group 0.000 description 2
125000006075 1-ethyl-3-butenyl group Chemical group 0.000 description 2
125000006028 1-methyl-2-butenyl group Chemical group 0.000 description 2
125000006048 1-methyl-2-pentenyl group Chemical group 0.000 description 2
125000006030 1-methyl-3-butenyl group Chemical group 0.000 description 2
125000006055 1-methyl-4-pentenyl group Chemical group 0.000 description 2
125000006067 2,2-dimethyl-3-butenyl group Chemical group 0.000 description 2
125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 2
125000006070 2,3-dimethyl-3-butenyl group Chemical group 0.000 description 2
125000006077 2-ethyl-2-butenyl group Chemical group 0.000 description 2
125000006078 2-ethyl-3-butenyl group Chemical group 0.000 description 2
125000006040 2-hexenyl group Chemical group 0.000 description 2
125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 2
125000006049 2-methyl-2-pentenyl group Chemical group 0.000 description 2
125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 2
125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 2
125000006056 2-methyl-4-pentenyl group Chemical group 0.000 description 2
125000006024 2-pentenyl group Chemical group 0.000 description 2
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 2
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 2
125000006041 3-hexenyl group Chemical group 0.000 description 2
125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 2
125000006054 3-methyl-3-pentenyl group Chemical group 0.000 description 2
125000006057 3-methyl-4-pentenyl group Chemical group 0.000 description 2
125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 2
125000006042 4-hexenyl group Chemical group 0.000 description 2
125000006051 4-methyl-2-pentenyl group Chemical group 0.000 description 2
125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
125000006058 4-methyl-4-pentenyl group Chemical group 0.000 description 2
125000006043 5-hexenyl group Chemical group 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
108700021041 Disintegrin Proteins 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
102000016359 Fibronectins Human genes 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
108060008245 Thrombospondin Proteins 0.000 description 2
102000002938 Thrombospondin Human genes 0.000 description 2
108010031318 Vitronectin Proteins 0.000 description 2
102100035140 Vitronectin Human genes 0.000 description 2
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical compound [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
210000002997 osteoclast Anatomy 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 2
125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 2
125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 2
125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 2
125000000168 pyrrolyl group Chemical group 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
125000001425 triazolyl group Chemical group 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
229920002554 vinyl polymer Polymers 0.000 description 2
108010047303 von Willebrand Factor Proteins 0.000 description 2
102100036537 von Willebrand factor Human genes 0.000 description 2
229960001134 von willebrand factor Drugs 0.000 description 2
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
CCPHAMSKHBDMDS-UHFFFAOYSA-N Chetoseminudin B Natural products C=1NC2=CC=CC=C2C=1CC1(SC)NC(=O)C(CO)(SC)N(C)C1=O CCPHAMSKHBDMDS-UHFFFAOYSA-N 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
108010012088 Fibrinogen Receptors Proteins 0.000 description 1
241000545744 Hirudinea Species 0.000 description 1
241000728904 Iais Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100022337 Integrin alpha-V Human genes 0.000 description 1
108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000034827 Neointima Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
102000004264 Osteopontin Human genes 0.000 description 1
108010081689 Osteopontin Proteins 0.000 description 1
101150044441 PECAM1 gene Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
102000007000 Tenascin Human genes 0.000 description 1
108010008125 Tenascin Proteins 0.000 description 1
108010048673 Vitronectin Receptors Proteins 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
150000005417 aminobenzoic acid derivatives Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
210000002805 bone matrix Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
108010073977 decorsin Proteins 0.000 description 1
125000005879 dioxolanyl group Chemical group 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
244000144980 herd Species 0.000 description 1
125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
230000008692 neointimal formation Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000003331 prothrombotic effect Effects 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
229940107685 reopro Drugs 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
230000015590 smooth muscle cell migration Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
125000001302 tertiary amino group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Oncology (AREA)
Biochemistry (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
Epidemiology (AREA)
Crystallography & Structural Chemistry (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Virology (AREA)

CA002371604A 1999-04-28 2000-04-17 Integrin receptor antagonists Abandoned CA2371604A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DE1999119218 DE19919218A1 (de)	1999-04-28	1999-04-28	Neue Integrinrezeptorantagonisten
DE19919218.9		1999-04-28
DE1999148269 DE19948269A1 (de)	1999-10-06	1999-10-06	Neue Integrinrezeptorantagonisten
DE19948269.1		1999-10-06
PCT/EP2000/003469 WO2000066618A1 (de)	1999-04-28	2000-04-17	Integrinrezeptorantagonisten

Publications (1)

Publication Number	Publication Date
CA2371604A1 true CA2371604A1 (en)	2000-11-09

Family

ID=26053109

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002371604A Abandoned CA2371604A1 (en)	1999-04-28	2000-04-17	Integrin receptor antagonists

Country Status (19)

Country	Link
EP (1)	EP1173468A1 (pt)
JP (1)	JP2003500339A (pt)
KR (1)	KR20020010618A (pt)
CN (1)	CN1355811A (pt)
AU (1)	AU4551500A (pt)
BG (1)	BG106040A (pt)
BR (1)	BR0010092A (pt)
CA (1)	CA2371604A1 (pt)
CZ (1)	CZ20013846A3 (pt)
HK (1)	HK1046692A1 (pt)
HU (1)	HUP0202898A2 (pt)
IL (1)	IL146146A0 (pt)
MX (1)	MXPA01010834A (pt)
NO (1)	NO20015237L (pt)
PL (1)	PL352777A1 (pt)
RU (1)	RU2001132141A (pt)
SK (1)	SK15342001A3 (pt)
TR (1)	TR200103090T2 (pt)
WO (1)	WO2000066618A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10204789A1 (de) *	2002-02-06	2003-08-14	Merck Patent Gmbh	Inhibitoren des Integrins alpha¶v¶beta6
KR100759130B1 (ko) *	2005-02-12	2007-09-19	휴메드 주식회사	항 인테그린 항체 코팅스텐트 및 그의 제조방법
US8716320B2 (en) *	2006-07-21	2014-05-06	Replidyne, Inc.	Antibacteriall heterocyclic ureas
WO2009015193A1 (en)	2007-07-23	2009-01-29	Replidyne, Inc.	Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds
EP2200440B1 (en)	2007-07-23	2017-07-19	Crestone, Inc.	Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
BRPI1012581A2 (pt) *	2009-06-02	2016-03-29	Boehringer Ingelheim Int	derivados de amidas de ácido 6, 7-di-hidro-5h-imidazol[1,2-a]imidazol-3-carboxílico
US9586916B2 (en) *	2012-01-27	2017-03-07	Hoffmann-La Roche Inc.	Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3
RU2731807C1 (ru) *	2020-05-05	2020-09-08	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт ревматологии имени В.А.Насоновой» (ФГБНУ НИИР им. В.А. Насоновой)	Способ определения показаний к началу приема генно-инженерных биологических препаратов при неэффективности базисных противовоспалительных препаратов при ранних формах псориатического артрита
EP4698170A1 (en) *	2023-04-21	2026-02-25	Eberhard-Karls-Universität Tübingen	Glycinamide derivatives for use in the treatment of salmonellosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX9801716A (es) *	1995-08-30	1998-05-31	Searle & Co	Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
GB2327609A (en) *	1997-07-23	1999-02-03	Merck & Co Inc	A method for eliciting an avß5 or dual avß3/avß5 antagonizing effect
EP0928790B1 (en) *	1998-01-02	2003-03-05	F. Hoffmann-La Roche Ag	Thiazole derivatives
KR20010042614A (ko) *	1998-04-10	2001-05-25	윌리암스 로저 에이	비트로넥틴 길항제로서 복소환식 글리실 베타-알라닌 유도체

2000
- 2000-04-17 RU RU2001132141/04A patent/RU2001132141A/ru unknown
- 2000-04-17 IL IL14614600A patent/IL146146A0/xx unknown
- 2000-04-17 JP JP2000615647A patent/JP2003500339A/ja active Pending
- 2000-04-17 CN CN00808907A patent/CN1355811A/zh active Pending
- 2000-04-17 KR KR1020017013790A patent/KR20020010618A/ko not_active Ceased
- 2000-04-17 AU AU45515/00A patent/AU4551500A/en not_active Abandoned
- 2000-04-17 EP EP00926971A patent/EP1173468A1/de not_active Withdrawn
- 2000-04-17 CZ CZ20013846A patent/CZ20013846A3/cs unknown
- 2000-04-17 MX MXPA01010834A patent/MXPA01010834A/es unknown
- 2000-04-17 WO PCT/EP2000/003469 patent/WO2000066618A1/de not_active Ceased
- 2000-04-17 HK HK02107883.3A patent/HK1046692A1/zh unknown
- 2000-04-17 HU HU0202898A patent/HUP0202898A2/hu unknown
- 2000-04-17 CA CA002371604A patent/CA2371604A1/en not_active Abandoned
- 2000-04-17 TR TR2001/03090T patent/TR200103090T2/xx unknown
- 2000-04-17 SK SK1534-2001A patent/SK15342001A3/sk unknown
- 2000-04-17 PL PL00352777A patent/PL352777A1/xx not_active Application Discontinuation
- 2000-04-17 BR BR0010092-7A patent/BR0010092A/pt not_active IP Right Cessation
2001
- 2001-10-23 BG BG106040A patent/BG106040A/bg unknown
- 2001-10-26 NO NO20015237A patent/NO20015237L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL352777A1 (en)	2003-09-08
BG106040A (bg)	2002-05-31
IL146146A0 (en)	2002-07-25
RU2001132141A (ru)	2004-03-20
KR20020010618A (ko)	2002-02-04
WO2000066618A1 (de)	2000-11-09
HUP0202898A2 (hu)	2002-12-28
NO20015237L (no)	2001-12-21
MXPA01010834A (es)	2002-04-24
CN1355811A (zh)	2002-06-26
BR0010092A (pt)	2002-06-11
AU4551500A (en)	2000-11-17
JP2003500339A (ja)	2003-01-07
TR200103090T2 (tr)	2002-05-21
NO20015237D0 (no)	2001-10-26
HK1046692A1 (zh)	2003-01-24
SK15342001A3 (sk)	2002-06-04
EP1173468A1 (de)	2002-01-23
CZ20013846A3 (cs)	2002-06-12

Legal Events

Date	Code	Title	Description
2001-10-24	EEER	Examination request
2007-04-17	FZDE	Discontinued

Publication	Publication Date	Title
US10781189B2 (en)	2020-09-22	1,2,4-Oxadiazole and thiadiazole compounds as immunomodulators
AU765294B2 (en)	2003-09-11	Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
JP2008513508A (ja)	2008-05-01	炎症及び免疫に関連する用途に用いる化合物
ES2393188T3 (es)	2012-12-19	Compuestos heterocíclicos que se unen a los receptores de quimiocina y presentan eficacia mejorada
JP2001509176A (ja)	2001-07-10	インテグリンアンタゴニスト
JP2002521450A (ja)	2002-07-16	インテグリン受容体アンタゴニスト
JP2009514954A (ja)	2009-04-09	Ｔｒｐｖ３機能を変調するための化合物
US20100048536A1 (en)	2010-02-25	Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands
CN101537001A (zh)	2009-09-23	作为jak-stat3信号通路抑制剂的化合物的应用
CN105530948A (zh)	2016-04-27	对天然cxcr4具有拮抗活性的肽
CA2368049A1 (en)	2000-10-19	Integrin receptor ligands
TW201006823A (en)	2010-02-16	Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
KR20020019974A (ko)	2002-03-13	신규한 인테그린 수용체 길항제
EP1371646B1 (en)	2010-05-19	Aryl-substituted alicyclic compound and medical composition comprising the same
WO2012112919A1 (en)	2012-08-23	Stromal derived factor inhibition and cxcr4 blockade
CA3149590A1 (en)	2021-03-04	Fused polypeptide and use thereof
Rosenbloom et al.	2008	Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis.
BG106040A (bg)	2002-05-31	Интегрин - рецепторни антагонисти
JP2004522800A (ja)	2004-07-29	インテグリン受容体のリガンドとしての置換されたピリミジノン誘導体
KR20220009442A (ko)	2022-01-24	암 치료, 케모카인 활성 억제 및/또는 세포사 유도를 위한 소분자
CN113072467B (zh)	2022-04-12	含取代胍基衍生物及其在制备破骨细胞分化抑制剂上的应用
DE10027514A1 (de)	2002-01-03	Liganden von Integrinrezeptoren
CN104109118B (zh)	2018-07-24	邻吡啶酰肼衍生物及其制法和药物组合物与用途
JP2011512364A (ja)	2011-04-21	治療用ペプチド
ZA200108555B (en)	2002-10-18	Integrin receptor antagonists.